Taunia Markvicka
CIK 1545282 · View on SEC EDGAR ↗
Insider
First SEC filing: March 29, 2012 · Latest: March 29, 2012
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net:
$0
+ 17 non-open-market transactions below
last 12 months, based on the transactions shown below
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
17 other filings hidden
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| May 15, 2017 | CRMD | P | 14,500 | $0.51 | $7,395 | 37,100 Direct | +64.16% | Acquired | 234.5% (price as of 2026-08-20) |
| Aug. 25, 2016 | CRMD | P | 18,600 | $1.65 | $30,690 | 22,600 Direct | +465.00% | Acquired | 3.4% (price as of 2026-08-20) |
| June 23, 2015 | CRMD | P | 4,000 | $4.81 | $19,240 | 4,000 Direct | — | Acquired | -64.5% (price as of 2026-08-20) |
| Nov. 7, 2014 | PCRX | P | 230 | $86.62 | $19,923 | 230 Indirect | — | Acquired | -72.2% (price as of 2026-08-20) |
| Nov. 6, 2013 | PCRX | S 10b5-1 | 1,802 | $53.61 | $96,605 | 0 Direct | -100.00% | Disposed | -55.1% (price as of 2026-08-20) |
| Nov. 6, 2013 | PCRX | S 10b5-1 | 5,681 | $52.49 | $298,196 | 1,802 Direct | -75.92% | Disposed | -54.1% (price as of 2026-08-20) |
| Nov. 6, 2013 | PCRX | S 10b5-1 | 14,123 | $51.36 | $725,357 | 7,483 Direct | -65.37% | Disposed | -53.1% (price as of 2026-08-20) |
| Nov. 6, 2013 | PCRX | S 10b5-1 | 28,394 | $50.60 | $1,436,736 | 21,606 Direct | -56.79% | Disposed | -52.4% (price as of 2026-08-20) |
| Sept. 25, 2013 | PCRX | S 10b5-1 | 10,000 | $47.00 | $470,000 | 0 Direct | -100.00% | Disposed | -48.8% (price as of 2026-08-20) |
| Aug. 14, 2013 | PCRX | S 10b5-1 | 14,700 | $37.00 | $543,900 | 0 Direct | -100.00% | Disposed | -34.9% (price as of 2026-08-20) |
| July 12, 2013 | PCRX | S 10b5-1 | 29,754 | $32.00 | $952,128 | 0 Direct | -100.00% | Disposed | -24.7% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 21, 2017 | CRMD | Stock Option (Right to Buy Common Stock) | Common Stock (40,000) | $2.24 | Feb. 21, 2027 | 40,000 | Acquired |
| Feb. 21, 2017 | CRMD | Restricted Stock Units | Common Stock (13,571) | — | — | 13,571 | Acquired |
| Feb. 22, 2016 | CRMD | Stock Option (right to buy) | Common Stock (90,000) | $1.91 | Feb. 21, 2026 | 90,000 | Acquired |
| March 17, 2015 | PCRX | Employee Stock Option (Right to Buy) | Common Stock (8,349) | $5.49 | Dec. 28, 2020 | 8,349 | Disposed |
| March 2, 2015 | CRMD | Stock Option (right to buy) | Common Stock, $0.001 par value per share (50,000) | $5.62 | March 1, 2025 | 50,000 | Acquired |
| June 3, 2014 | PCRX | Stock Option (Right to Buy) | Common Stock (70,000) | $81.00 | June 3, 2024 | 70,000 | Acquired |
| April 4, 2014 | CRMD | Stock Option (right to buy) | Common Stock, $0.001 par value per share (30,000) | $2.05 | April 3, 2024 | 30,000 | Acquired |
| Nov. 6, 2013 | PCRX | Employee Stock Option (right to buy) | Common Stock (50,000) | $10.81 | June 4, 2022 | 50,000 | Disposed |
| Sept. 25, 2013 | PCRX | Employee Stock Option (right to buy) | Common Stock (10,000) | $5.49 | Dec. 28, 2020 | 10,000 | Disposed |
| Aug. 14, 2013 | PCRX | Employee Stock Option (right to buy) | Common Stock (14,700) | $1.61 | Sept. 1, 2020 | 14,700 | Disposed |
| July 12, 2013 | PCRX | Employee Stock Option (right to buy) | Common Stock (29,754) | $1.61 | Sept. 1, 2020 | 29,754 | Disposed |
| June 5, 2012 | PCRX | Common Stock | Common Stock (150,000) | $10.81 | June 4, 2022 | 150,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 3 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| March 29, 2012 | PCRX | Employee Stock Option (right to buy)→ Common Stock (21,385) | 21,385 | Direct |
| March 29, 2012 | PCRX | Employee Stock Option (right to buy)→ Common Stock (29,754) | 29,754 | Direct |
| March 29, 2012 | PCRX | Employee Stock Option (right to buy)→ Common Stock (18,349) | 18,349 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2014 | $353,160 | $150,000 | — | $2,980,099 | — | — | $630 | $3,483,889 |
| 2013 | $318,900 | $140,000 | — | — | — | — | $630 | $459,530 |
| 2012 | $315,000 | $65,000 | — | $1,062,015 | — | — | $436 | $1,442,451 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.